Formulation and Drug Delivery, Other

September 15th 2023

AI’s role in target discovery and manufacturing optimization remained the most chosen application looking three years ahead; however, approximately 43% envision that it will help to build base regulatory submissions.

September 7th 2023

Optibrium announced on Aug. 31, 2023 the acquisition of BioPharmics to further expand the 3D drug design and modelling offering and to focus on research and development and application science.

August 9th 2023

SBS-518 is a first-in-class dual sigma receptor (SR) antagonist/dopamine transporter (DAT) inhibitor in development for the treatment of stimulant use disorder (StUD).

March 23rd 2023

Advancements in therapeutic modalities are necessitating change in drug delivery to help negate some of the expense of development and manufacturing.